{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse%2C+Large+B-cell+Lymphoma&page=33", "query": { "condition": "Diffuse, Large B-cell Lymphoma", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 1246, "total_pages": 125, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse%2C+Large+B-cell+Lymphoma&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse%2C+Large+B-cell+Lymphoma&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T08:24:50.390Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06890884", "title": "A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Zilovertamab vedotin", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Rituximab Biosimilar", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 594, "start_date": "2025-04-11", "completion_date": "2032-12-16", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 73, "location_summary": "Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06890884" }, { "nct_id": "NCT05784415", "title": "Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia", "Leukemia, Lymphoblastic", "Lymphoma, Large B-Cell, Diffuse", "Follicular Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Follicular", "Lymphoma, Non-Hodgkin", "HIV Infections", "HIV Associated Lymphoma", "HIV Disease; Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-05-22", "completion_date": "2024-11-14", "has_results": true, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05784415" }, { "nct_id": "NCT02203526", "title": "Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Isavuconazole", "type": "DRUG" }, { "name": "TEDDI", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "TEDD", "type": "DRUG" }, { "name": "Ibrutinib (Arms 2, 3 and 4)", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ibrutinib (Arm 1 - Closed with Amendment G)", "type": "DRUG" }, { "name": "Ibrutinib (Arm 4)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 68, "start_date": "2014-08-14", "completion_date": "2028-06-15", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02203526" }, { "nct_id": "NCT01472887", "title": "SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "SAR3419", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2012-01", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2018-01-25", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 3, "location_summary": "Denver, Colorado • Augusta, Georgia • Boise, Idaho", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01472887" }, { "nct_id": "NCT04512716", "title": "Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "B-ALL", "DLBCL", "B ALL", "Dlbcl-Ci", "DLBCL Unclassifiable", "DLBCL, Nos Genetic Subtypes", "DLBCL Activated B-Cell Type", "DLBCL Germinal Center B-Cell Type", "Diffuse Large B-cell Lymphoma", "HGBL", "HGBL, Nos" ], "interventions": [ { "name": "131-I Apamistamab", "type": "DRUG" }, { "name": "CAR T-cell", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-02-02", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04512716" }, { "nct_id": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "High Grade B-Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 20, "start_date": "2026-12-08", "completion_date": "2031-10-08", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07714421" }, { "nct_id": "NCT05757219", "title": "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Chimeric antigen receptor (CAR) T-cell therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-05-19", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05757219" }, { "nct_id": "NCT02631044", "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Mantle-cell Lymphoma", "Primary Mediastinal B-cell Lymphoma" ], "interventions": [ { "name": "JCAR017 (lisocabtagene maraleucel) single-dose schedule", "type": "BIOLOGICAL" }, { "name": "JCAR017 (lisocabtagene maraleucel) 2-dose schedule", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 387, "start_date": "2016-01-06", "completion_date": "2024-05-16", "has_results": false, "last_update_posted_date": "2024-06-27", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631044" }, { "nct_id": "NCT06667687", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "ABBV-291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2025-01-16", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 5, "location_summary": "Huntersville, North Carolina • Eugene, Oregon • Austin, Texas + 2 more", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Eugene", "state": "Oregon" }, { "city": "Austin", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06667687" }, { "nct_id": "NCT00216164", "title": "Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2005-04", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2011-05-02", "last_synced_at": "2026-10-30T08:24:50.390Z", "location_count": 9, "location_summary": "Elkhart, Indiana • Evansville, Indiana • Fort Wayne, Indiana + 4 more", "locations": [ { "city": "Elkhart", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216164" } ] }